Astellas Pharma : Announces Personnel Changes and Organizational Changes (pdf 395KB)

Press Release

Astellas Announces Personnel Changes and Organizational Changes

Tokyo, February 8, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

1. Appointments of Senior Corporate Executive effective on April 1, 2017

   Name	New Title	Current Title
   Yasumasa Masuda	CEO's Office	CFO
   Kenji Yasukawa	CSTO & CCO	CSTO
   Mitsunori Matsuda	President, Pharmaceutical Technology	President, Technology

   CEO: Chief Executive Officer CFO: Chief Financial Officer CSTO: Chief Strategy Officer CCO: Chief Commercial Officer

2. Appointments of Corporate Executive effective on April 1, 2017

   Name	New Title	Current Title
   Kiyotaka Hayashi	CEO's Office	Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing
   Chikashi Takeda	CFO	Corporate Vice President, Corporate Finance & Control
   Fumiaki Sakurai	CAO & CECO	Corporate Vice President, Human Resources
   Akihiko Iwai	Divisional Senior Vice President, Candidate Discovery Science Labs., DDR	Divisional Senior Vice President, Research Portfolio & Science, DDR
   Toru Yoshimitsu	Corporate Vice President, Corporate Finance & Control	Corporate Vice President, Product & Portfolio Strategy
   Taiji Sawamoto	Vice President, Research Program Management, DDR	Vice President, Clinical Pharmacology, Development

   CAO: Chief Administrative Officer

   CECO: Chief Ethics & Compliance Officer DDR: Drug Discovery Research

3. Resignation of Senior Corporate Executive effective on June 19, 2017

   Name	Title (effective on April 1, 2017)
   Yasumasa Masuda	CEO's Office

4. Resignation of Corporate Executive effective on June 19, 2017

   Name	Title (effective on April 1, 2017)
   Kiyotaka Hayashi	CEO's Office

5. Appointment of Senior Corporate Executive effective on June 19th, 2017

   Name	Title (effective on April 1, 2017)
   Masatoshi Kuroda	President, Asia & Oceania Business

6. New Corporate Executives effective on June 19, 2017

   Name	Title (effective on April 1, 2017)
   Tadashi Hara	Divisional Senior Vice President, Strategic Business Management, Japan Sales & Marketing
   Hideki Shima	Divisional Senior Vice President, Technology Planning & Administration, Pharmaceutical Technology
   Shigeki Tanaka	Vice President, Japan-Asia Clinical Development 1, Development

7. Personnel Changes effective on April 1, 2017

   Name	New Title	Current Title
   Linda Friedman	General Counsel	Senior Vice President, General Counsel, Astellas US LLC
   Koichiro Morihira	Head of Intellectual Property	Vice President, Intellectual Property
   Naoki Sogo	Corporate Vice President, Product & Portfolio Strategy	Executive Director, Product & Portfolio Strategy
   Akira Kamimura	Vice President, Accounting & Tax	Executive Director, Corporate Finance & Control
   Yasuhiro Tsutsui	Vice President, Executive Office	Executive Director, Strategic Business Management, Japan Sales & Marketing

   Ryusuke Nakajima	Corporate Vice President, Human Resources	Executive Director, Human Resources
   Noriyuki Masuda	Vice President, Research Planning & Administration, DDR	Divisional Senior Vice President, Research Administration, DDR
   Rika Hirota	Vice President, Research Regulatory Management, DDR	Vice President, Bioscience Research Labs., DDR
   Yuichi Tomura	Vice President, Research Portfolio Planning, DDR	Executive Director, Innovation & Research Portfolio Planning, DDR
   Shunichiro Matsumoto	Divisional Senior Vice President, Innovation & Incubation Research Labs., DDR	Vice President, Innovation Management
   Shigeki Kawabata	Vice President, Evolving Medical Solutions, DDR	Vice President, Evolving Medical Solutions
   Masaaki Hirano	Divisional Senior Vice President, Modality Research Labs., DDR	Vice President, Medicinal Chemistry Research Labs., DDR
   Manabu Murakami	Vice President, Clinical Pharmacology, Development	Executive Director, Astellas Institute for Regenerative Medicine
   Yuzuru Komano	Vice President, Japan-Asia Clinical Development 2, Development	Senior Director, Japan-Asia Clinical Development 2, Development
   Manabu Beppu	Vice President, Japan-Asia Data Science, Development	Vice President, Japan-Asia Clinical Development Administration, Development
   Yasushi Ikeda	Vice President, Medical Science Liaison, Medical Affairs Japan	Vice President, Medical Research, Medical Affairs Japan
   Katsutoshi Nakamura	Vice President, Project & Product Management, Pharmaceutical Technology	Vice President, Technology Product Management, Technology
   Nobuyuki Tanaka	Vice President, Supply Chain Management, Pharmaceutical Technology	President, Astellas US Technologies, Inc.

   Kazuhiko Hayashida	Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing	General Manager, Chugoku Branch, Japan Sales & Marketing
   Masao Toda	General Manager, Saitama Branch, Japan Sales & Marketing	Executive Director, Tokyo Branch, Japan Sales & Marketing
   Yoshiyuki Naoi	General Manager, Chugoku Branch, Japan Sales & Marketing	General Manager, Shikoku Branch, Japan Sales & Marketing
   Yuusuke Kumagai	General Manager, Shikoku Branch, Japan Sales & Marketing	Executive Director, Human Resources Development, Japan Sales & Marketing
   Katsushi Takenaka	General Manager, Kyushu Branch, Japan Sales & Marketing	General Manager, Saitama Branch, Japan Sales & Marketing
   Hiroshi Hamaguchi	Vice President, Business Planning, Asia & Oceania Business	Head of South East & South Asia
   Keita Masujima	Vice President, Marketing, Asia & Oceania Business	Vice President, Business Planning, Asia & Oceania Business

8. Organizational Changes effective on April 1, 2017

Executive Office

Executive Office will expand its roles and responsibilities to support a globalized Astellas' Top Management structure in an effective way and to better respond to a shift to stricter corporate governance in Japan.

Drug Discovery Research

To precisely and rapidly respond to changes in the healthcare environment and continuously create innovation on the forefront of such changes, Drug Discovery Research will be reorganized as the Attachment 1.

Japan-Asia Clinical Development Administration

To strengthen global alignment and increase business efficiency, Japan-Asia Clinical Development Administration will be dissolved. The medical writing function and the clinical development administration function will be incorporated into Japan-Asia Data Science and Japan-Asia Planning & Administration respectively.